Featured Content
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Myeloma News
Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Source: Myeloma - Hematology Advisor Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests. Read More
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
Source: Myeloma - Hematology Advisor High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests. Read More
Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance
Source: Myeloma : nature.com subject feeds Post Content Read More
Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Source: Myeloma : nature.com subject feeds Post Content Read More
Trajectory of Relapsed/Refractory Multiple Myeloma Treatment Landscape
Source: OncLive articles In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma. Read More
Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma
Source: Myeloma - Hematology Advisor Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Read More
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Source: Myeloma : nature.com subject feeds Post Content Read More
Body Mass Index Tied to Multiple Myeloma Survival
Source: Myeloma - Hematology Advisor Decreased survival seen for both underweight and severe obesity in newly diagnosed patients. Read More
Recent Publications
Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
J Clin Oncol. 2023 Mar 20:JCO2202665. doi: 10.1200/JCO.22.02665. Online ahead of print. NO ABSTRACT PMID:36940404 | DOI:10.1200/JCO.22.02665
Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients
Clin Transl Med. 2023 Mar;13(3):e1224. doi: 10.1002/ctm2.1224. NO ABSTRACT PMID:36938997 | DOI:10.1002/ctm2.1224
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer J. 2023 Mar 20;13(1):40. doi: 10.1038/s41408-023-00807-9. ABSTRACT Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of...
Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Blood Cancer J. 2023 Mar 20;13(1):39. doi: 10.1038/s41408-023-00814-w. NO ABSTRACT PMID:36935437 | DOI:10.1038/s41408-023-00814-w
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma
Qual Life Res. 2023 Mar 20. doi: 10.1007/s11136-023-03390-5. Online ahead of print. ABSTRACT PURPOSE: The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items as proxy...
Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling
Front Immunol. 2023 Mar 2;14:982720. doi: 10.3389/fimmu.2023.982720. eCollection 2023. ABSTRACT INTRODUCTION: Proteasome inhibition is first line therapy in multiple myeloma (MM). The immunological potential of cell death triggered by defects of the...
Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma
Transplant Cell Ther. 2023 Mar 16:S2666-6367(23)01171-5. doi: 10.1016/j.jtct.2023.03.012. Online ahead of print. ABSTRACT BACKGROUND: Risks of B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy for patients with multiple myeloma (MM)...
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Nat Med. 2023 Mar 17. doi: 10.1038/s41591-023-02306-7. Online ahead of print. NO ABSTRACT PMID:36932247 | DOI:10.1038/s41591-023-02306-7
